BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. Gastroenterology 2020;159:849-63. [PMID: 32569766 DOI: 10.1053/j.gastro.2020.04.077] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Peng J, Zhu S, Yu L, Tian F, Zhao J, Zhang H, Chen W, Zhai Q. A screening model for probiotics against specific metabolic diseases based on caco-2 monolayer membrane. Engineering 2022. [DOI: 10.1016/j.eng.2022.02.014] [Reference Citation Analysis]
2 Xu B, Zheng J, Tian X, Yuan F, Liu Z, Zhou Y, Yang Z, Ding X. Protective mechanism of traditional Chinese medicine guizhi fuling pills against carbon tetrachloride-induced kidney damage is through inhibiting oxidative stress, inflammation and regulating the intestinal flora. Phytomedicine 2022;101:154129. [DOI: 10.1016/j.phymed.2022.154129] [Reference Citation Analysis]
3 McPherson AC, Pandey SP, Bender MJ, Meisel M. Systemic Immunoregulatory Consequences of Gut Commensal Translocation. Trends Immunol 2021;42:137-50. [PMID: 33422410 DOI: 10.1016/j.it.2020.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Zhang Z, Li M, Cui B, Chen X. Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. Front Pharmacol 2022;13:829686. [DOI: 10.3389/fphar.2022.829686] [Reference Citation Analysis]
5 Zhao Q, Song SY, Zhang YQ, Ren X, Zhang P, Li X, Fu XM, Wang CY. The underlying mechanisms of anti-hepatitis B effects of formula Le-Cao-Shi and its single herbs by network pharmacology and gut microbiota analysis. Biomed Pharmacother 2022;148:112692. [PMID: 35151160 DOI: 10.1016/j.biopha.2022.112692] [Reference Citation Analysis]
6 Hijová E. Synbiotic Supplements in the Prevention of Obesity and Obesity-Related Diseases. Metabolites 2022;12:313. [DOI: 10.3390/metabo12040313] [Reference Citation Analysis]
7 Niu H, Feng X, Shi C, Zhang D, Chen H, Huang H, Jiang Y, Wang J, Cao X, Wang N, Zeng Y, Yang G, Yang W, Wang C. Gut Bacterial Composition and Functional Potential of Tibetan Pigs Under Semi-Grazing. Front Microbiol 2022;13:850687. [DOI: 10.3389/fmicb.2022.850687] [Reference Citation Analysis]
8 Hu Q, Zhang W, Wu Z, Tian X, Xiang J, Li L, Li Z, Peng X, Wei S, Ma X, Zhao Y. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects. Pharmacol Res 2021;165:105444. [PMID: 33493657 DOI: 10.1016/j.phrs.2021.105444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Fiaschini N, Negroni A, Palone F, Vitali R, Colantoni E, Laudadio I, Mancuso M, Cucchiara S, Stronati L. Colonic inflammation accelerates the progression of liver disease: A protective role of dipotassium glycyrrhizate. Dig Liver Dis 2021:S1590-8658(21)00854-9. [PMID: 34903499 DOI: 10.1016/j.dld.2021.11.015] [Reference Citation Analysis]
10 Haderer M, Neubert P, Rinner E, Scholtis A, Broncy L, Gschwendtner H, Kandulski A, Pavel V, Mehrl A, Brochhausen C, Schlosser S, Gülow K, Kunst C, Müller M. Novel pathomechanism for spontaneous bacterial peritonitis: disruption of cell junctions by cellular and bacterial proteases. Gut 2021:gutjnl-2020-321663. [PMID: 33707230 DOI: 10.1136/gutjnl-2020-321663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Vanuytsel T, Tack J, Farre R. The Role of Intestinal Permeability in Gastrointestinal Disorders and Current Methods of Evaluation. Front Nutr 2021;8:717925. [PMID: 34513903 DOI: 10.3389/fnut.2021.717925] [Reference Citation Analysis]
12 Xie X, Zhou J, Hu L, Shu R, Zhang M, Xiong Z, Wu F, Fu Z. Exposure to hexafluoropropylene oxide dimer acid (HFPO-DA) disturbs the gut barrier function and gut microbiota in mice. Environ Pollut 2021;290:117934. [PMID: 34416495 DOI: 10.1016/j.envpol.2021.117934] [Reference Citation Analysis]
13 Sun TY, Li YQ, Zhao FQ, Sun HM, Gao Y, Wu B, Yang S, Ji FQ, Zhou DS. MiR-1-3p and miR-124-3p synergistically damage the intestinal barrier in the aging colon. J Crohns Colitis 2021:jjab179. [PMID: 34628497 DOI: 10.1093/ecco-jcc/jjab179] [Reference Citation Analysis]
14 Chen Y, Qiao L, Song X, Ma L, Dou X, Xu C. Protective Effects of Selenium Nanoparticle-Enriched Lactococcus lactis NZ9000 against Enterotoxigenic Escherichia coli K88-Induced Intestinal Barrier Damage in Mice. Appl Environ Microbiol 2021;87:e0163621. [PMID: 34524898 DOI: 10.1128/AEM.01636-21] [Reference Citation Analysis]
15 Yan S, Yin XM. Gut microbiome in liver pathophysiology and cholestatic liver disease. Liver Res 2021;5:151-63. [PMID: 35355516 DOI: 10.1016/j.livres.2021.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Song W, Sun LY, Zhu ZJ. Effects of Previous Kasai Surgery on Gut Microbiota and Bile Acid in Biliary Atresia With End-Stage Liver Disease. Front Med (Lausanne) 2021;8:704328. [PMID: 34646837 DOI: 10.3389/fmed.2021.704328] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Xiong K, Cai J, Liu P, Wang J, Zhao S, Xu L, Yang Y, Liu J, Ma A. Lactobacillus casei Alleviated the Abnormal Increase of Cholestasis-Related Liver Indices During Tuberculosis Treatment: A Post Hoc Analysis of Randomized Controlled Trial. Mol Nutr Food Res 2021;65:e2100108. [PMID: 33864432 DOI: 10.1002/mnfr.202100108] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Plaza-Díaz J, Solís-Urra P, Rodríguez-Rodríguez F, Olivares-Arancibia J, Navarro-Oliveros M, Abadía-Molina F, Álvarez-Mercado AI. The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. Int J Mol Sci 2020;21:E8351. [PMID: 33171747 DOI: 10.3390/ijms21218351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
19 Blesl A, Stadlbauer V. The Gut-Liver Axis in Cholestatic Liver Diseases. Nutrients 2021;13:1018. [PMID: 33801133 DOI: 10.3390/nu13031018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Rao B, Ren T, Wang X, Wang H, Zou Y, Sun Y, Liu S, Ren Z, Yu Z. Dysbiosis in the Human Microbiome of Cholangiocarcinoma. Front Physiol 2021;12:715536. [PMID: 34867436 DOI: 10.3389/fphys.2021.715536] [Reference Citation Analysis]
21 Wu J, Bortolanza M, Zhai G, Shang A, Ling Z, Jiang B, Shen X, Yao Y, Yu J, Li L, Cao H. Gut microbiota dysbiosis associated with plasma levels of Interferon-γ and viral load in patients with acute hepatitis E infection. J Med Virol 2022;94:692-702. [PMID: 34549810 DOI: 10.1002/jmv.27356] [Reference Citation Analysis]
22 Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week. J Am Coll Cardiol 2022;79:180-91. [PMID: 35027111 DOI: 10.1016/j.jacc.2021.11.007] [Reference Citation Analysis]
23 Ikejima K, Kon K, Yamashina S. Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights. Clin Mol Hepatol 2020;26:728-35. [PMID: 33053942 DOI: 10.3350/cmh.2020.0202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Floreani A, De Martin S, Ikeura T, Okazaki K, Gershwin ME. Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis. Expert Opinion on Orphan Drugs 2020;8:507-14. [DOI: 10.1080/21678707.2020.1865917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
26 Zhang Y, Li JX, Zhang Y, Wang YL. Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis . World J Clin Cases 2021; 9(23): 6654-6662 [PMID: 34447812 DOI: 10.12998/wjcc.v9.i23.6654] [Reference Citation Analysis]
27 Chen Q, Xu L, Wu T, Li J, Hua L. Analysis of abnormal intestinal flora on risk of intestinal cancer and effect of heparin on formation of bacterial biofilm. Bioengineered 2022;13:894-904. [PMID: 34968154 DOI: 10.1080/21655979.2021.2014388] [Reference Citation Analysis]
28 Li S, Zhuge A, Wang K, Lv L, Bian X, Yang L, Xia J, Jiang X, Wu W, Wang S, Wang Q, Li L. Ketogenic diet aggravates colitis, impairs intestinal barrier and alters gut microbiota and metabolism in DSS-induced mice. Food Funct 2021;12:10210-25. [PMID: 34542110 DOI: 10.1039/d1fo02288a] [Reference Citation Analysis]
29 Liwinski T, Heinemann M, Schramm C. The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts. Semin Immunopathol 2022. [PMID: 35536431 DOI: 10.1007/s00281-022-00936-6] [Reference Citation Analysis]
30 Liu F, Sun C, Chen Y, Du F, Yang Y, Wu G. Indole-3-propionic Acid-aggravated CCl4-induced Liver Fibrosis via the TGF-β1/Smads Signaling Pathway. J Clin Transl Hepatol 2021;9:917-30. [PMID: 34966655 DOI: 10.14218/JCTH.2021.00032] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Cunningham AL, Stephens JW, Harris DA. A review on gut microbiota: a central factor in the pathophysiology of obesity. Lipids Health Dis 2021;20:65. [PMID: 34233682 DOI: 10.1186/s12944-021-01491-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Pan Y, Zhang X. Diet and gut microbiome in fatty liver and its associated liver cancer. J Gastroenterol Hepatol 2021. [PMID: 34664301 DOI: 10.1111/jgh.15713] [Reference Citation Analysis]
33 Ay Ü, Leníček M, Classen A, Olde Damink SWM, Bolm C, Schaap FG. New Kids on the Block: Bile Salt Conjugates of Microbial Origin. Metabolites 2022;12:176. [DOI: 10.3390/metabo12020176] [Reference Citation Analysis]
34 Xiang J, Zhang Z, Xie H, Zhang C, Bai Y, Cao H, Che Q, Guo J, Su Z. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Gut Microbes 2021;13:1949095. [PMID: 34313539 DOI: 10.1080/19490976.2021.1949095] [Reference Citation Analysis]
35 Xia J, Lv L, Liu B, Wang S, Zhang S, Wu Z, Yang L, Bian X, Wang Q, Wang K, Zhuge A, Li S, Yan R, Jiang H, Xu K, Li L. Akkermansia muciniphila Ameliorates Acetaminophen-Induced Liver Injury by Regulating Gut Microbial Composition and Metabolism. Microbiol Spectr 2022;:e0159621. [PMID: 35107323 DOI: 10.1128/spectrum.01596-21] [Reference Citation Analysis]
36 Xie X, Geng C, Li X, Liao J, Li Y, Guo Y, Wang C. Roles of gastrointestinal polypeptides in intestinal barrier regulation. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170753] [Reference Citation Analysis]
37 Xu Q, Zhang R, Mu Y, Song Y, Hao N, Wei Y, Wang Q, Mackay CR. Propionate Ameliorates Alcohol-Induced Liver Injury in Mice via the Gut-Liver Axis: Focus on the Improvement of Intestinal Permeability. J Agric Food Chem 2022. [PMID: 35549256 DOI: 10.1021/acs.jafc.2c00633] [Reference Citation Analysis]
38 Chancharoenthana W, Leelahavanichkul A, Ariyanon W, Vadcharavivad S, Phatcharophaswattanakul S, Kamolratanakul S, Leaungwutiwong P, Phumratanaprapin W, Wilairatana P. Leaky Gut Syndrome Is Associated with Endotoxemia and Serum (1→3)-β-D-Glucan in Severe Dengue Infection. Microorganisms 2021;9:2390. [PMID: 34835514 DOI: 10.3390/microorganisms9112390] [Reference Citation Analysis]
39 Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol 2021;49:194-202. [PMID: 34242953 DOI: 10.1016/j.coviro.2021.06.006] [Reference Citation Analysis]
40 Liu Y, Huang W, Wang J, Ma J, Zhang M, Lu X, Liu J, Kou Y. Multifaceted Impacts of Periodontal Pathogens in Disorders of the Intestinal Barrier. Front Immunol 2021;12:693479. [PMID: 34386004 DOI: 10.3389/fimmu.2021.693479] [Reference Citation Analysis]
41 Gao W, Zhu Y, Ye J, Chu H. Gut non-bacterial microbiota contributing to alcohol-associated liver disease. Gut Microbes 2021;13:1984122. [PMID: 34711112 DOI: 10.1080/19490976.2021.1984122] [Reference Citation Analysis]
42 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
43 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]
44 Chuaypen N, Jinato T, Avihingsanon A, Chirapongsathorn S, Cheevadhanarak S, Nookaew I, Tanaka Y, Tangkijvanich P. Improvement of Gut Diversity and Composition after Direct-Acting Antivirals in HCV-Infected Patients with or without HIV Coinfection. J Infect Dis 2021:jiab094. [PMID: 33598686 DOI: 10.1093/infdis/jiab094] [Reference Citation Analysis]
45 Han B, Lee GB, Yim SY, Cho K, Shin KE, Kim J, Park Y, Han K, Kim Y. Non-Alcoholic Fatty Liver Disease Defined by Fatty Liver Index and Incidence of Heart Failure in the Korean Population: A Nationwide Cohort Study. Diagnostics 2022;12:663. [DOI: 10.3390/diagnostics12030663] [Reference Citation Analysis]
46 Fan J, Sun J, Li T, Yan X, Jiang Y. Nuciferine prevents hepatic steatosis associated with improving intestinal mucosal integrity, mucus-related microbiota and inhibiting TLR4/MyD88/NF-κB pathway in high-fat induced rats. Journal of Functional Foods 2022;88:104859. [DOI: 10.1016/j.jff.2021.104859] [Reference Citation Analysis]
47 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
48 Sun X, Cui Q, Ni J, Liu X, Zhu J, Zhou T, Huang H, OuYang K, Wu Y, Yang Z. Gut Microbiota Mediates the Therapeutic Effect of Monoclonal Anti-TLR4 Antibody on Acetaminophen-Induced Acute Liver Injury in Mice. Microbiol Spectr 2022;:e0064722. [PMID: 35536057 DOI: 10.1128/spectrum.00647-22] [Reference Citation Analysis]
49 Enomoto M, Kaji K, Nishimura N, Fujimoto Y, Murata K, Takeda S, Tsuji Y, Fujinaga Y, Takaya H, Kawaratani H, Namisaki T, Akahane T, Yoshiji H. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis. Dig Liver Dis 2022:S1590-8658(22)00257-2. [PMID: 35514019 DOI: 10.1016/j.dld.2022.04.012] [Reference Citation Analysis]
50 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
51 Wang C, Ma C, Fu K, Gong LH, Zhang YF, Zhou HL, Li YX. Phillygenin Attenuates Carbon Tetrachloride-Induced Liver Fibrosis via Modulating Inflammation and Gut Microbiota. Front Pharmacol 2021;12:756924. [PMID: 34621179 DOI: 10.3389/fphar.2021.756924] [Reference Citation Analysis]
52 Lin S, Wu F, Cao Z, Liu J. Advances in Nanomedicines for Interaction with the Intestinal Barrier. Advanced NanoBiomed Research. [DOI: 10.1002/anbr.202100147] [Reference Citation Analysis]
53 Zhu W, Zhou Y, Tsao R, Dong H, Zhang H. Amelioratory Effect of Resistant Starch on Non-alcoholic Fatty Liver Disease via the Gut-Liver Axis. Front Nutr 2022;9:861854. [DOI: 10.3389/fnut.2022.861854] [Reference Citation Analysis]
54 Zheng Z, Xiao Y, Ma L, Lyu W, Peng H, Wang X, Ren Y, Li J. Low Dose of Sucralose Alter Gut Microbiome in Mice. Front Nutr 2022;9:848392. [DOI: 10.3389/fnut.2022.848392] [Reference Citation Analysis]
55 Hu Y, He J, Zheng P, Mao X, Huang Z, Yan H, Luo Y, Yu J, Luo J, Yu B, Chen D. Prebiotic inulin as a treatment of obesity related nonalcoholic fatty liver disease through gut microbiota: a critical review. Crit Rev Food Sci Nutr 2021;:1-11. [PMID: 34292103 DOI: 10.1080/10408398.2021.1955654] [Reference Citation Analysis]
56 Åberg F, Helenius-hietala J. Oral Health and Liver Disease: Bidirectional Associations—A Narrative Review. Dentistry Journal 2022;10:16. [DOI: 10.3390/dj10020016] [Reference Citation Analysis]
57 Chen Y, Sun J, Fan X, Wang X, Zeng L, Zhang X, Zhang K, Li N, Han Q, Liu Z. Association of 5-Hydroxytryptamine 3 Receptor Antagonists With the Prognosis of Liver Failure. Front Pharmacol 2021;12:648736. [PMID: 33967787 DOI: 10.3389/fphar.2021.648736] [Reference Citation Analysis]
58 Fang S, Wang T, Li Y, Xue H, Zou J, Cai J, Shi R, Wu J, Ma Y. Gardenia jasminoides Ellis polysaccharide ameliorates cholestatic liver injury by alleviating gut microbiota dysbiosis and inhibiting the TLR4/NF-κB signaling pathway. Int J Biol Macromol 2022:S0141-8130(22)00292-6. [PMID: 35176320 DOI: 10.1016/j.ijbiomac.2022.02.056] [Reference Citation Analysis]